Novel immunomodulatory markers expressed by human WJ-MSC: An updated review in regenerative and reparative medicine

Open Tissue Engineering and Regenerative Medicine Journal

Volumn 5, Issue 1, 2012, Pages 50-58

  la Rocca, Giampiero ^a,b   Corrao, Simona ^b   Lo Iacono, Melania ^b   Corsello, Tiziana ^b   Farina, Felicia ^a   Anzalone, Rita ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Istituto Euro Mediterraneo di Scienza e Tecnologia IEMEST   (Italy)

Author keywords

Differentiation; Hypoimmunogenicity; Immune modulation; Inflammation; Matrix metalloproteinases; Mesenchymal stem cells; Regenerative medicine; Tissue repair; Umbilical cord; Wharton's jelly

Indexed keywords

5' NUCLEOTIDASE; BETA1 INTEGRIN; CD200 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENDOGLIN; GELATINASE A; GELATINASE B; HERMES ANTIGEN; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DR ANTIGEN; THY 1 ANTIGEN; TRANSCRIPTION FACTOR FOXP3; VON WILLEBRAND FACTOR; B7 ANTIGEN; CD14 ANTIGEN; CD27 ANTIGEN; CD271 ANTIGEN; CD276 ANTIGEN; CD68 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; HLA E ANTIGEN; HLA F ANTIGEN; HLA G ANTIGEN; LEUKEMIA INHIBITORY FACTOR; LYMPHOCYTE ANTIGEN; MATRIX METALLOPROTEINASE; PROGRAMMED DEATH 1 LIGAND 1; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1;

AMNION; AMNION CELL; ANTIGEN EXPRESSION; ARTICLE; BIOMEDICINE; CELL DIFFERENTIATION; CELL POPULATION; CELL THERAPY; HUMAN; IMMUNITY; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; MESENCHYMAL STROMA CELL; MICROENVIRONMENT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REPARATIVE MEDICINE; TISSUE REPAIR; UMBILICAL CORD; UMBILICAL CORD BLOOD; WHARTON JELLY; COMPARATIVE EFFECTIVENESS; CYTOKINE PRODUCTION; ENZYME ACTIVITY; IMMUNOREGULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; THERAPY EFFECT; THROMBOCYTOPENIA;

EID: 84870997378     PISSN: None     EISSN: 18750435     Source Type: Journal    
DOI: 10.2174/1875043501205010050     Document Type: Article

References (111)

1. Karahuseyinoglu S, Cinar O, Kilic E, et al. Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys. Stem Cells 2007; 25: 319-31.
2. Hoyes AD Ultrastructure of the epithelium of the human umbilical cord. J Anat 1969; 150: 149-62.
3. McElreavey KD, Irvine AI, Ennis KT, McLean WH. Isolation, culture and characterisation of fibroblast-like cells derived from the Wharton's jelly portion of human umbilical cord. Biochem Soc Trans 1991; 19: 29S.
4. Kobayashi K, Kubota T, Aso T. Study on myofibroblast differentiation in the stromal cells of Wharton's jelly: expression and localization of alpha-smooth muscle actin. Early Hum Dev 1998; 51: 223-33.
5. Nanaev AK, Kohnen G, Milovanov AP, Domogatsky SP, Kaufmann P. Stromal differentiation and architecture of the human umbilical cord. Placenta 1998; 18: 53-64.
6. Copland IB, Adamson SL, Post M, Lye SJ, Caniggia I. TGF-β3 expression during umbilical cord development and its alteration in pre-eclampsia. Placenta 2012; 23, 311-21.
7. Mizoguchi M, Suga Y, Sanmano B, Ikeda S, Ogawa H. Organotypic culture and surface plantation using umbilical cord epithelial cells: morphogenesis and expression of differentiation markers mimicking cutaneous epidermis. J Dermatol Sci 2004; 35: 199-206.
8. Jeschke MG, Gauglitz GG, Phan TT, Herndon DN, Kita K. Umbilical Cord Lining Membrane and Wharton's Jelly-Derived Mesenchymal Stem Cells: the Similarities and Differences. Open Tissue Eng Regen Med J 2011; 4: 21-7.
9. Mitchell KE, Weiss ML, Mitchell BM, et al. Matrix cells from Wharton's jelly form neurons and glia. Stem Cells 2003; 21: 50-60.
10. Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE. Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells 2005; 23: 220-9.
11. Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I, Fisk NM. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001; 98: 2396-402.
12. Kita K, Gauglitz GG, Phan TT, Herndon DN, Jeschke MG. Isolation and characterization of mesenchymal stem cells from the sub-amniotic human umbilical cord lining membrane. Stem Cells Dev 2010; 19: 491-502.
13. Wang H-S, Hung S-C, Peng S-T, et al. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells 2004; 22: 1330-7.
14. Weiss ML, Medicetty S, Bledsoe AR, et al. Human umbilical cord matrix stem cells: Preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Stem Cells 2006; 24: 781-92.
15. Lu LL, Liu Yj, Yang SG, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoietic supportive function and other potentials. Haematologica 2006; 91: 1017-26.
16. La Rocca G, Anzalone R, Corrao S, et al. Isolation and characterization of Oct-4+/HLA-G+ mesenchymal stem cells from human umbilical cord matrix: differentiation potential and detection of new markers. Histochem Cell Biol 2009; 131: 267-82.
17. La Rocca G, Anzalone R, Farina F. The expression of CD68 in human umbilical cord mesenchymal stem cells: New evidences of presence in non-myeloid cell types. Scand J Immunol 2009; 70: 161-2.
18. Huang Y, Parolini O, La Rocca G, Deng L. Umbilical cord versus bone marrow-derived mesenchymal stromal cells. Stem Cells Dev 2012; 21(5): 2900-3.
19. Lo Iacono M, Anzalone R, Corrao S, et al. Perinatal and Wharton's Jelly-Derived Mesenchymal Stem Cells in Cartilage Regenerative Medicine and Tissue Engineering Strategies. Open Tissue Eng Regen Med J 2011; 4: 72-81.
20. Dominici M, Le Blanc K, Mueller I et al. E. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006; 8: 315-7.
21. Anzalone R, Lo Iacono M, Loria T, et al. Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: Extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes. Stem Cell Rev Rep 2011; 7: 342-63.
22. Anzalone R, Farina F, Zummo G, La Rocca G. Recent patents and advances on isolation and cellular therapy applications of mesenchymal stem cells from human umbilical cord Wharton's jelly. Rec Pat Regen Med 2011; 1: 216-27.
23. Conconi MT, Burra P, Di Liddo R, et al. CD105(+) cells from Wharton's jelly show in vitro and in vivo myogenic differentiative potential. Int J Mol Med 2006; 18: 1089-96.
24. Pereira WC, Khushnooma I, Madkaikar M, Ghosh K. Reproducible methodology for the isolation of mesenchymal stem cells from human umbilical cord and its potential for cardiomyocyte generation. J Tissue Eng Regen Med 2008; 2: 394-9.
25. Hollweck T, Hartmann I, Eblenkamp M, et al. Cardiac differentiation of human wharton's jelly stem cells-experimental comparison of protocols. Open Tissue Eng Regen Med J 2011; 4: 95-102.
26. Anzalone R, La Rocca G, Di Stefano A, et al. Role of endothelial cell stress in the pathogenesis of chronic heart failure. Front Biosci 2009; 14: 2238-47.
27. Alaminos M, Pérez-Köhler B, Garzón I, et al. Transdifferentiation potentiality of human Wharton's jelly stem cells towards vascular endothelial cells. J Cell Physiol 2010; 223: 640-7.
28. La Rocca G, Di Stefano A, Eleuteri E, et al. Oxidative stress induces myeloperoxidase expression in endocardial endothelial cells from patients with chronic heart failure. Basic Res Cardiol 2009; 104: 307-20.
29. Campard D, Lysy PA, Najimi M, Sokal EM. Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells. Gastroenterology 2008; 134: 833-48.
30. Anzalone R, Lo Iacono M, Corrao S, et al. New emerging potentials for human Wharton's jelly mesenchymal stem cells: immunological features and hepatocyte-like differentiative capacity. Stem Cells Dev 2010; 19: 423-38.
31. Semenov OV, Breymann C. Mesenchymal stem cells derived from wharton's jelly and their potential for cardio-vascular tissue engineering. Open Tissue Eng Regen Med J 2011; 4: 64-71.
32. Yokokawa M, Ohnishi S, Ishibashi-Ueda H, et al. Transplantation of mesenchymal stem cells improves atrioventricular conduction in a rat model of complete atrioventricular block. Cell Transplant 2008; 17: 1145-55.
33. Turillazzi E, La Rocca G, Anzalone R, et al. Heterozygous nonsense SCN5A mutation W822X explains a simultaneous sudden infant death syndrome. Virchows Arch 2008; 453: 209-16.
34. Turillazzi E, Pomara C, La Rocca G, et al. Immunohistochemical marker for Na+ CP type Valpha (C-20) and heterozygous nonsense SCN5A mutation W822X in a sudden cardiac death induced by mild anaphylactic reaction. Appl Immunohistochem Mol Morphol 2009; 17: 357-62.
35. Micklem K, Rigney E, Cordell J, et al. A human macrophageassociated antigen (CD68) detected by six different monoclonal antibodies. Br J Haematol 1989; 73: 6-11.
36. Gottfried E, Kunz-Schughart LA, Weber A, et al. Expression of CD68 in non-myeloid cell types. Scand J Immunol 2008; 67: 453-63.
37. Turnovcova K, Ruzickova K, Vanecek V, Sykova E, Jendelova P. Properties and growth of human bone marrow mesenchymal stromal cells cultivated in different media. Cytotherapy 2009; 11: 874-85.
38. Troyer DL, Weiss ML. Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells 2008; 26: 591-9.
39. Wang HS, Hung SC, Peng ST, et al. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells 2004; 22: 1330-7.
40. Deuse T, Stubbendorff M, Tang-Quan K, et al. Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant 2011; 20: 655-67.
41. Al-Nbaheen M, Vishnubalaji R, Ali D, et al. Human stromal (mesenchymal) stem cells from bone marrow, adipose tissue and skin exhibit differences in molecular phenotype and differentiation potential. Stem Cell Rev Rep 2012; doi:10.1007/s12015-012-9365-8
42. Magatti M, De Munari S, Vertua E, Gibelli L, Wengler GS, Parolini O. Human amnion mesenchyme harbors cells with allogeneic T-cell suppression and stimulation capabilities. Stem Cells 2008; 26:182-92.
43. Götherström C, West A, Liden J, Uzunel M, Lahesmaa R, Le Blanc K. Difference in gene expression between human fetal liver and adult bone marrow mesenchymal stem cells. Haematologica 2005; 90:1017-26.
44. Chen H, Zhang N, Li T, et al. Human umbilical cord Wharton's jelly stem cells: immune property genes assay and effect of transplantation on the immune cells of heart failure patients. Cell Immunol 2012; 276: 83-90.
45. Anzalone R, Lo Iacono M, Corrao S, et al. Human Wharton's jellyderived mesenchymal stem cells express several immunomodulatory molecules both in their naïve state and hepatocyte-like differentiated progeny: prospects for their use in liver diseases. Placenta 2011; 32(Supplement 4): S335.
46. Weiss ML, Anderson C, Medicetty S, et al. Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells 2008; 26: 2865-74.
47. Selmani Z, Naji A, Zidi I, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26: 212-22.
48. Lee JM, Jung J, Lee HJ, et al. Comparison of immunomodulatory effects of placenta mesenchymal stem cells with bone marrow and adipose mesenchymal stem cells. Int Immunopharmacol 2012; 13: 219-24.
49. Banas RA, Trumpower C, Bentlejewski C, Marshall V, Sing G, Zeevi A. Immunogenicity and immunomodulatory effects of amnion-derived multipotent progenitor cells. Hum Immunol 2008; 69: 321-8.
50. Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 2000; 28: 875-84.
51. Hoogduijn MJ, Crop MJ, Peeters AM, et al. Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities. Stem Cells Dev 2007; 16: 597-604.
52. Xu W, Zhang X, Qian H, et al. Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro. Exp Biol Med 2004; 229: 623-31.
53. Sheng H, Wang Y, Jin Y, et al. A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res 2008; 18: 846-57.
54. Tipnis S, Viswanathan C, Majumdar AS. Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO. Immunol Cell Biol 2010; 88: 795-806.
55. Niehage C, Steenblock C, Pursche T, Bornhäuser M, Corbeil D, Hoflack B. The cell surface proteome of human mesenchymal stromal cells. PLoS One 2011; 6: e20399.
56. Lo Iacono M, Anzalone R, Corrao S, Zummo G, Farina F, La Rocca G. Non-classical type I HLAs and B7 costimulators revisited: analysis of expression and immunomodulatory role in undifferentiated and differentiated MSC isolated from human umbilical cord Wharton's jelly. Histol Histopathol 2011; 26(Supplement 1): 313.
57. Xue Q, Luan XY, Gu YZ, et al. The negative co-signaling molecule b7-h4 is expressed by human bone marrow-derived mesenchymal stem cells and mediates its T-cell modulatory activity. Stem Cells Dev 2010; 19: 27-38.
58. Németh K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15: 42-9.
59. Yañez R, Oviedo A, Aldea M, Bueren JA, Lamana ML. Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. Exp Cell Res 2010; 316: 3109-23.
60. Kang JW, Koo HC, Hwang SY, et al. Immunomodulatory effects of human amniotic membrane-derived mesenchymal stem cells. J Vet Sci 2012; 13: 23-31.
61. Najar M, Raicevic G, Boufker HI, et al. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell Immunol 2010; 264: 171-9.
62. Liu T, Guo L, Liu Z, Cheng W. Human amniotic epithelial cells maintain mouse spermatogonial stem cells in an undifferentiated state due to high leukemia inhibitor factor (LIF) expression. in Vitro Cell Dev Biol Anim 2011; 47: 318-26.
63. Mathieu ME, Saucourt C, Mournetas V, et al. LIF-dependent signaling: new pieces in the Lego. Stem Cell Rev Rep 2012; 8: 1-15.
64. Potdar PD, D'Souza SB. Ascorbic acid induces in vitro proliferation of human subcutaneous adipose tissue derived mesenchymal stem cells with upregulation of embryonic stem cell pluripotency markers Oct4 and SOX 2. Hum Cell 2010; 23: 152-5.
65. Najar M, Raicevic G, Boufker HI, et al. Adipose-tissue-derived and Wharton's jelly-derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor. Tissue Eng Part A 2010; 16: 3537-46.
66. Pietilä M, Lehtonen S, Tuovinen E, et al. CD200 positive human mesenchymal stem cells suppress tnf-alpha secretion from cd200 receptor positive macrophage-like cells. PLoS One 2012; 7: e31671.
67. Delorme B, Ringe J, Gallay N, et al. Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells. Blood 2008; 111: 2631-5.
68. Najar M, Raicevic G, Jebbawi F, et al. Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes. Immunol Lett 2012; 146: 50-6.
69. Soncini M, Vertua E, Gibelli L, et al. Isolation and characterization of mesenchymal cells from human fetal membranes. J Tissue Eng Regen Med 2007; 1: 296-305.
70. Quirici N, Scavullo C, de Girolamo L, Lopa S, Arrigoni E, Deliliers GL, Brini AT. Anti-L-NGFR and-CD34 monoclonal antibodies identify multipotent mesenchymal stem cells in human adipose tissue. Stem Cells Dev 2010; 19: 915-25.
71. Kuçi S, Kuçi Z, Kreyenberg H, et al. CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica 2010; 95: 651-9.
72. Margossian T, Reppel L, Makdissy N, Stoltz JF, Bensoussan D, Huselstein C. Mesenchymal stem cells derived from Wharton's jelly: Comparative phenotype analysis between tissue and in vitro expansion. Biomed Mater Eng 2012; 22: 243-54.
73. Smith M, Bittner JG 4th, White S, Smith D, Horuzsko A. HLA-Gtreated tolerogenic dendritic cells induce tolerogenic potential by increasing expression of B7-1 (CD80) molecules. Transplant Proc 2008; 40: 1598-603.
74. Kurtz J, Raval F, Vallot C, Der J, Sykes M. CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance. Blood 2009; 113: 3475-84.
75. Zhu X-Y, Zhou Y-H, Wang M-Y, Jin L-P, Yuan M-M, Li D-J. Blockade of CD86 signaling facilitates a Th2 bias at the maternal-fetal interface and expands peripheral CD4+CD25+ regulatory T cells to rescue abortion-prone fetuses. Biol Reprod 2005; 72: 338-45.
76. Anzalone R, Corrao S, Lo Iacono M, et al. Isolation and characterization of CD276+/HLA-E+ human sub-endocardial mesenchymal stem cells from chronic heart failure patients: analysis of differentiative potential and immunomodulatory markers expression. Stem Cells Dev 2012; doi:10.1089/scd.2012.0402.
77. Cappello F, Czarnecka AM, La Rocca G, Di Stefano A, Zummo G, Macario AJ. Hsp60 and Hspl0 as antitumor molecular agents. Cancer Biol Ther 2007; 6: 487-9.
78. Corrao S, Campanella C, Anzalone R, et al. Human Hsp10 and Early Pregnancy Factor (EPF) and their relationship and involvement in cancer and immunity: current knowledge and perspectives. Life Sci 2010; 86: 145-52.
79. Lee N, Llano M, Carretero M, et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci USA 1998; 95: 5199-204.
80. Ishitani A, Sageshima N, Lee N, et al. Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition. J Immunol 2003; 171: 1376-84
81. Shobu T, Sageshima N, Tokui H, et al. The surface expression of HLA-F on decidual trophoblasts increases from mid to term gestation. J Reprod Immunol 2006; 72: 18-32.
82. Boyle LH, Gillingham AK, Munro S, Trowsdale J. Selective export of HLA-F by its cytoplasmic tail. J Immunol 2006; 176: 6464-72.
83. Goodridge JP, Burian A, Lee N, Geraghty DE. HLA-F complex without peptide binds to MHC class I protein in the open conformer form. J Immunol 2010; 184: 6199-208.
84. Parham P, Norman PJ, Abi-Rached L, Guethlein LA. Humanspecific evolution of killer cell immunoglobulin-like receptor recognition of major histocompatibility complex class I molecule. Philos Trans R Soc B 2012; 367: 800-11.
85. Griffin MD, Ritter T, Mahon BP. Immunological aspects of allogeneic mesenchymal stem cell therapies. Human Gene Ther 2010; 21: 1641-55.
86. Díaz-Lagares A, Alegre E, LeMaoult J, Carosella ED, González A. Nitric oxide produces HLA-G nitration and induces metalloprotease-dependent shedding creating a tolerogenic milieu. Immunology 2009; 126: 436-45.
87. Eleuteri E, Magno F, Gnemmi I, et al. Role of oxidative and nitrosative stress biomarkers in chronic heart failure. Front Biosci 2009; 14: 2230-7.
88. Eleuteri E, Di Stefano A, Ricciardolo FL, et al. Increased nitrotyrosine plasma levels in relation to systemic markers of inflammation and myeloperoxidase in chronic heart failure. Int J Cardiol 2009; 135: 386-90.
89. Rogers ML, Beare A, Zola H, Rush RA. Cd271 (P75 neurotrophin receptor). J Biol Regul Homeost Agents 2008; 22: 1-6.
90. La Rocca G. Connecting the dots: the promises of Wharton's jelly mesenchymal stem cells for tissue repair and regeneration. Open Tissue Eng Regen Med J 2011; 4: 3-5.
91. Prasanna SJ, Jahnavi VS. Wharton's Jelly Mesenchymal Stem Cells as Off-The-Shelf Cellular Therapeutics: A Closer Look into their Regenerative and Immunomodulatory Properties. Open Tissue Eng Regen Med J 2011; 4: 28-38
92. Prasanna SJ, Gopalakrishnan D, Shankar SR, Vasandan AB. Proinflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One 2010; 5: e9016.
93. Zhou C, Yang B, Tian Y, et al. Immunomodulatory effect of human umbilical cord Wharton's jelly-derived mesenchymal stem cells on lymphocytes. Cell Immunol 2011; 272: 33-8.
94. Shohara R, Yamamoto A, Takikawa S, Iwase A, Hibi H, Kikkawa F, Ueda M. Mesenchymal stromal cells of human umbilical cord Wharton's jelly accelerate wound healing by paracrine mechanisms. Cytotherapy 2012; 14(10): 1171-81.
95. Raicevic G, Najar M, Pieters K, et al. Inflammation and toll-like receptor ligation differentially affect the osteogenic potential of human mesenchymal stromal cells depending on their tissue origin. Tissue Eng Part A 2012; 18: 1410-8.
96. Raicevic G, Najar M, Stamatopoulos B, et al. The source of human mesenchymal stromal cells influences their TLR profile as well as their functional properties. Cell Immunol 2011; 270: 207-16.
97. Ma L, Zhou Z, Zhang D, et al. Immunosuppressive function of mesenchymal stem cells from human umbilical cord matrix in immune thrombocytopenia patients. Thromb Haemost 2012; 107: 937-50.
98. De Miguel MP, Fuentes-Julián S, Blázquez-Martínez A, et al. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med 2012; 12: 574-91.
99. Turner NA, Porter KE. Regulation of myocardial matrix metalloproteinase expression and activity by cardiac fibroblasts. IUBMB Life 2012; 64: 143-50.
100. La Rocca G, Anzalone R, Magno F, Farina F, Cappello F, Zummo G. Cigarette smoke exposure inhibits extracellular MMP-2 (gelatinase A) activity in human lung fibroblasts. Respir Res 2007; 8: 23.
101. La Rocca G, Pucci-Minafra I, Marrazzo A, Taormina P, Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 2004; 90: 1414-21.
102. Pucci-Minafra I, Minafra S, La Rocca G, et al. Zymographic analysis of circulating and tissue forms of colon carcinoma gelatinase A (MMP-2) and B (MMP-9) separated by mono-and two-dimensional electrophoresis. Matrix Biol 2001; 20: 419-27.
103. Pitiyage GN, Slijepcevic P, Gabrani A, et al. Senescent mesenchymal cells accumulate in human fibrosis by a telomereindependent mechanism and ameliorate fibrosis through matrix metalloproteinases. J Pathol 2011; 223: 604-17.
104. Griffin M, Iqbal SA, Sebastian A, Colthurst J, Bayat A. Degenerate wave and capacitive coupling increase human MSC invasion and proliferation while reducing cytotoxicity in an in vitro wound healing model. PLoS One 2011; 6: e23404.
105. Kanematsu D, Shofuda T, Yamamoto A, et al. Isolation and cellular properties of mesenchymal cells derived from the decidua of human term placenta. Differentiation 2011; 82: 77-88.
106. Huang W, Wang T, Zhang D, et al. Mesenchymal stem cells overexpressing CXCR4 attenuate remodeling of postmyocardial infarction by releasing matrix metalloproteinase-9. Stem Cells Dev 2012; 21: 778-89.
107. Qiu Y, Marquez-Curtis LA, Janowska-Wieczorek A. Mesenchymal stromal cells derived from umbilical cord blood migrate in response to complement C1q. Cytotherapy 2012; 14: 285-95.
108. Studer D, Millan C, Oztürk E, Maniura-Weber K, Zenobi-Wong M. Molecular and biophysical mechanisms regulating hypertrophic differentiation in chondrocytes and mesenchymal stem cells. Eur Cell Mater 2012; 24: 118-35.
109. Li H, Feng F, Bingham CO 3rd, Elisseeff JH. Matrix metalloproteinases and inhibitors in cartilage tissue engineering. J Tissue Eng Regen Med 2012; 6: 144-54.
110. Davatchi F, Abdollahi BS, Mohyeddin M, Shahram F, Nikbin B. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. Int J Rheum Dis 2011; 14: 211-5.
111. Yeung TY, Seeberger KL, Kin T, et al. Human mesenchymal stem cells protect human islets from pro-inflammatory cytokines. PLoS One 2012; 7: e38189.